Ansseau M, Fischler B, Dierick M, Mignon A, Leyman S. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxembourg: the GADIS study. Eur Psychiatry. 2005;20:229-235.
Barone et al. Depressive symptoms in Parkinson's disease: results from the PRODEST-PD study. Poster P593, MDS 11th international congress of PD and Movement disorders. Istanbul, Turkey, June 3-7, 2007.
Barone et al. Depression and antidepressant use in Parkinson's disease: Results from the PRODEST-PD study. Poster P1122. 11th EFNS congress, Brussels, Belgium, August 25-28, 2007.
Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat Disord. 2003;9:S83-S89.
Celesia GG, Wanamaker WM. Psychiatric disturbances in Parkinson's disease. Dis Nerv Syst. 1972;33: 577-583.
Cummings JL. Depression and Parkinson's disease: a review . Am J Psych. 1992;149:443-454.
Cummings JL. Frontal-subcortical circuits and human behaviour . Arch Neurol. 1993;50:873-880.
Cummings JL, Masterman DL. Depression in patients with Parkinson' disease. Int J Geriatric Psychiatry. 1999;14:711-718.
DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000.
Fahn S, Elton RL, UPDRS program members. Unified Parkinson's Disease Rating Scale. In: "Recent developments in Parkinson's disease". Vol.2. Fahn S, Marsden CD, Goldstein M, Calne DB, eds., Florham Park, NJ: Macmillan Healthcare Information, 1987:153-163.
Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiat. 1988;51:745-752.
GPDSSC: Global Parkinson's Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord. 2002;17:60-67.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality, Neurology. 1967;17:427-442.
Lecrubier Y, Sheehan D, Weiller E, Amorim P, Bonora I. et al. The MINI International Neuropsychiatric Interview (M.I.N.I.) A Short Diagnostic Structured Interview: Reliability and Validity According to the CIDI. Eur Psychiatry. 1997;12:224-231.
Lieberman A. Depression in Parkinson's disease - a review . Acta Neurol Scand. 2006;113:1-8.
Mann JJ, Kapur S. A dopaminergic hypothesis of major depression. Clin Neuropharmacol. 1995;18:S57-S65.
McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biological Psychiatry. 2003;54:363-375.
Miyazaki JM, Shannon K, Voon V, Ravina B, Kleiner- Fisman G. et al. Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson's disease (an evidence-based review). Neurology. 2006;66:996-1002.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ; CARPA Study Group. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology. 2008;70:2241-2247.
Okun MS, Watts RL. Depression associated with Parkinson's disease: clinical features and treatment. Neurology 2002;58:S63-S70.
Reijnders JS, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A Systematic Review of Prevalence Studies of Depression in Parkinson's Disease. Mov Disord. 2008;23:183-189.
Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128:1314-1322.
Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's Disease? Neurol Neurosurg Psychiatry. 2000;69:308-312.
Schrag A.Quality of life and depression in Parkinson's disease. J Neurol Sci. 2006;248:151-157.
Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM. et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord . 2007;22:1077-1092.
Schuurman AG, van den Akker M, Ensinck KTJL, Metsemakers JMF, Knotterus JA. et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology. 2002;58:1501-1504.
Schwab RS, England AC Jr. Projection techniques for evaluating surgery in Parkinson's Disease. In: "Third Symposium on Parkinson's Disease", Royal College of Surgeons in Edinburgh, May 20-22, 1968. E. & S. Livingstone Ltd.;1969:152-157.
Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E. et al. Reliability and Validity of the MINI International Neuropsychiatric Interview (M.I.N.I.): According to the SCID-P. Eur Psychiatry. 1997;12:232-241.
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J. et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59:22-33.
Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's Disease. Parkinsonism Relat Disord. 2002; 8:193-197.
Snaith RP, Harrop FM, Newby DA, Teale C. Grade scores of the Montgomery-Asberg Depression and the Clinical Anxiety Scales. Br J Psychiatry. 1986;148: 599-601.
Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv. Ment. Dis. 1990;178:27-31.
Vanderheyden JE, Dekoninck WJ, Lefevre A, Mendlewicz J. Apports du test au probénécide au diagnostic et à la thérapeutique des parkinsoniens. L'Encéphale 1980; VI, 349-366.
Vanderheyden JE, Bourgeois P, Gonce M, Tack P. L'enquête "Tremor" en Belgique: approche du tremblement rebelle chez les patients parkin - soniens. Neurone. 2009;14:93-101.
Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C. et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord. 2005;20:1161-1169.
Willner P. The mesolimbic dopamine system as a target for a rapid antidepressant action. Int Clin Psychopharmacol. 1997;12:S7-S14.
